We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS

Abstract

Get full access to this article

View all access options for this article.

References

Wehner

Shopp

Osterburg

et al . Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol 2009; 86(2): 144–156.

Karlsson

Francis

Koren

et al . Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014; 82(8): 674–680.

Rothman

Greenland

Lash

TL.

Types of epidemiologic studies. In: Rothman

Greenland

Lash

(eds) Modern epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2008, pp. 87–99.

Confavreux

Hutchinson

Hours

et al . Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339(5): 285–291.

Thöne

Thiel

Gold

et al . Treatment of multiple sclerosis during pregnancy—safety considerations. Expert Opin Drug Saf 2017; 16(5): 523–534.

Giacomini

. Rebound disease in multiple sclerosis. Mult Scler 2018; 24(8): 1137–1138.

Thiel

Langer-Gould

Rockhoff

et al . Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler 2016; 22(6): 801–809.

Herbstritt

Langer-Gould

Rockhoff

et al . Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler 2016; 22(6): 810–816.

Haghikia

Langer-Gould

Rellensmann

et al . Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014; 71(7): 891–895.

10.

Benson

Hartz

. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342(25): 1878–1886.

We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS – No

Abstract

Get full access to this article

References